Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19100587 | 0.81 | FAAH (0.40) | FAAHELANEUSP2SMN1; SMN2BCHE | |
| SCHEMBL25318772 | 0.78 | FAAH (0.38) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL26712709 | 0.78 | FAAH (0.38) | FAAHELANEUSP2SMN1; SMN2 | |
| SCHEMBL3231153 | 0.77 | ALDH1A1 (0.47) | FAAHELANE | |
| SCHEMBL25317940 | 0.77 | FAAH (0.37) | FAAHELANEUSP2SMN1; SMN2GPR119 | |
| SCHEMBL10236319 | 0.74 | FAAH (0.40) | FAAHELANEUSP2SMN1; SMN2BCHE | |
| SCHEMBL3086177 | 0.74 | FAAH (0.40) | FAAHELANEUSP2SMN1; SMN2BCHE | |
| SCHEMBL32683506 | 0.72 | FAAH (0.39) | FAAHELANEGPR119L3MBTL1 | |
| SCHEMBL30676992 | 0.72 | ALDH1A1 (0.40) | FAAHELANE | |
| SCHEMBL6963629 | 0.71 | FAAH (0.38) | FAAHELANEUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767827-B2 | Pyrazole-1-carboxylate derivatives, process for the production thereof and process for the production of pyrazole derivatives | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1884512-A1 | PYRAZOLE-1-CARBOXYLIC ESTER DERIVATIVE, METHOD FOR PRODUCING THE SAME AND METHOD FOR PRODUCING PYRAZOLE DERIVATIVE | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 2008-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018345-A1 | PYRAZOLE-1-CARBOXYLATE DERIVATIVES, PROCESS FOR THE PRODUCTION THEREOF AND PROCESS FOR THE PRODUCTION OF PYRAZOLE DERIVATIVES | WEE1, CYP51A1, CYP4B1 | FAAH 2220/4885ELANE 4780/4885USP2 2712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.